pharma-reg-summary

name	pharma-reg-summary
description	Generates structured pharmaceutical regulatory compliance summaries covering FDA approval pathways, patent/IP intersections (Orange Book, Hatch-Waxman), and marketing restrictions (off-label, DTC, Anti-Kickback). Use when preparing FDA compliance overviews, submission readiness assessments, or promotional compliance reviews.

Pharmaceutical Regulation Compliance Summary

Produces an actionable regulatory compliance summary structured around FDA frameworks, patent/IP strategy, and promotional compliance.

Prerequisites

Gather before starting:

1. Product portfolio — marketed products, pipeline compounds, therapeutic areas
2. Regulatory filings — pending NDAs/ANDAs/BLAs, active INDs, post-approval commitments
3. Commercial activities — speaker programs, DTC campaigns, consulting arrangements
4. Compliance history — warning letters, consent decrees, audit findings

Quick Start

Structure every summary into three sections:

1. Drug Approval & Post-Market Obligations — pathway requirements, safety reporting, PMRs/PMCs
2. Patent & IP Regulatory Intersections — Orange Book, exclusivity, Hatch-Waxman
3. Marketing & Promotional Compliance — off-label rules, financial compliance, DTC advertising

Core Workflow

1. Drug Approval & Post-Market Obligations

Pathway	Requirements	Pitfalls
NDA 505(b)(1)	Full clinical data, CMC, labeling	Data integrity gaps, incomplete safety DBs
ANDA 505(j)	Bioequivalence, Para IV certs	Improper BE design, cert errors
BLA 351(a)	Biosimilarity/interchangeability	Analytical similarity gaps, immunogenicity
Expedited (BT/FT/AA)	Post-market confirmatory requirements	Missing confirmatory trial milestones

Per-product checklist:

• IND compliance (21 CFR 312): 7/15-day safety reports, annual reports, protocol amendments
• Data integrity (21 CFR 11): electronic records, GCP/GLP/GMP
• Post-market: FAERS reporting (15-day expedited, 90-day periodic), REMS if applicable
• PSURs/PBRERs for internationally marketed products
• PMR/PMC tracking with deadlines and escalation triggers

2. Patent & IP Regulatory Intersections

Framework	Authority	Key Points
Orange Book	21 CFR 314.53	Patent listings for drug/method of use; improper listings → antitrust risk
Purple Book	42 USC § 262	Reference product exclusivity, biosimilar interchangeability
Hatch-Waxman	21 USC § 355(j)(2)(A)(vii)	Para I–IV certs, 30-month stay, 180-day FTF exclusivity
Patent term extension	35 USC § 156	One per product; file within 60 days of approval
Pediatric exclusivity	21 USC § 355a	6-month addition; written request compliance required
NCE exclusivity	21 USC § 355(c)(3)(E)	5-year NCE, 3-year new clinical investigations

Flag in every summary:

• Patent strategy alignment with submission timelines
• Orange Book use code accuracy (delisting petition / FTC risk)
• Upcoming exclusivity expirations and generic/biosimilar entry risk

3. Marketing & Promotional Compliance

Off-label promotion — Prohibited under 21 USC § 331(d) (misbranding). Narrow exceptions: unsolicited requests (on-label redirect via medical affairs), peer-reviewed reprints under 21 USC § 360aaa. DOJ pursues under FCA theories.

Promotional materials — Fair balance required (21 CFR 202.1). Substantial evidence standard for efficacy claims. File Form FDA 2253 at first use.

Digital/social media — Follow FDA draft guidance for space-constrained formats. Monitor owned channels for misinformation. Disclose KOL/influencer arrangements per FTC + Sunshine Act.

DTC advertising — Broadcast: major statement + toll-free number/website. Print: brief summary of PI. Submit to OPDP; use Advisory Comment process for novel claims.

Financial compliance:

Statute	Key Rules
Anti-Kickback (42 USC § 1320a-7b)	Safe harbors: FMV compensation, written agreements, legitimate services
Sunshine Act (42 USC § 1320a-7h)	Report transfers of value >$10; track meals, consulting, speaking
FCA (31 USC § 3729)	Off-label promotion as predicate for FCA liability

Compliance Checklist

• SOPs for submissions, safety reporting, labeling updates
• Commercial team training on promotional boundaries (annual + new hire)
• MLR (medical-legal-regulatory) review of all promotional materials
• Audit program: labeling, ad claims, speaker program FMV
• PMR/PMC tracking with escalation triggers
• Whistleblower/compliance hotline and investigation protocols
• International harmonization assessment (EMA, PMDA) if applicable

Pitfalls

• Missing product-type distinctions — requirements differ for small molecule vs. biologic vs. generic; always separate
• Controlled substances — DEA scheduling overlay adds requirements; flag when applicable
• State law variance — state Sunshine laws and marketing consent statutes may impose additional obligations
• Stale citations — mark uncertain or recently updated authorities with [VERIFY]
• Scope creep — present regulatory facts; do not provide legal conclusions on enforcement risk — let counsel assess
• International gaps — if international operations exist, note material FDA vs. EMA differences